Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | -42.36% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.60 | N/A | -42.36% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach regarding future performance. They emphasized the importance of their clinical programs but did not offer specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.
Nektar Therapeutics reported a larger-than-expected loss for the quarter, which contributed to a slight decline in its stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term prospects. The stock's reaction reflects uncertainty as the company continues to focus on its clinical trials without clear financial direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
COGNIZANT TECHNOLOGY Class A
May 7, 2018